New strategies for the treatment of metastatic bone disease

Clinical Breast Cancer

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Pearse, Roger N ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bisphosphonates; c Src; Cathepsin K; Denosumab; Everolimus; Gallium; Mammalian target of rapamycin; Osteonecrosis; RANKL; Strontium; Teriparatide

Indexed keywords

7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; AMINOBISPHOSPHONATE DERIVATIVE; AP 23451; AP 23675; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K; CATHEPSIN K INHIBITOR; CLODRONIC ACID; DENOSUMAB; EVEROLIMUS; GALLIUM NITRATE; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MIV 701; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PHOSPHOTRANSFERASE INHIBITOR; RAPAMYCIN DERIVATIVE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RELACATIB; STRONTIUM RANELATE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITRONECTIN RECEPTOR; ZOLEDRONIC ACID;

BONE DESTRUCTION; BONE METASTASIS; BONE NECROSIS; BONE STRENGTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; ENZYME INHIBITION; HEARING LOSS; HUMAN; HYPERCALCEMIA; HYPOPHOSPHATEMIA; JAW DISEASE; KIDNEY FAILURE; LOADING DRUG DOSE; MYELOMA; NEPHROTOXICITY; ONCOGENE SRC; OPTIC NEURITIS; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; VERTEBRA FRACTURE;

EID: 38849181180     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.s.010     Document Type: Article

References (143)

1. Paget S. The distribution and secondary growths in cancer of the breast. Lancet 1889; 1:571-3.
2. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537-49.
3. Loberg RD, Gayed BA, Olson KB, et al. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J Cell Biochem 2005; 96:439-46.
4. Abildgaard N, Brixen K, Eriksen EF, et al. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004; 89:567-77.
5. Thurairaja R, lies RK, Jefferson K, et al. Serum amino-terminal propeptide of type 1 procollagen (PlNP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 2006; 76:67-71.
6. Franz-Odendaal TA, Hall BK, Witten PE. Buried alive: how osteoblasts become osteocytes. Dev Dyn 2006; 235:176-90.
7. Knothe Tate ML, Adamson JR, Tami AE, et al. The osteocyte. Int J Biochem Cell Biol 2004; 36:1-8.
8. Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci 2006; 1092:385-96.
9. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289:1504-8.
10. Roodman GD. Regulation of osteoclast differentiation. Ann N Y Acad Sci 2006; 1068:100-9.
11. Ross FP, Teitelbaum SL. Alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 2005; 208:88-105.
12. Dai XM, Ryan GR, Hapel AJ, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002; 99:111-20.
13. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-76.
14. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-19.
15. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186:2075-80.
16. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006; 107:3098-105.
17. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390:175-9.
18. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315-23.
19. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-24.
20. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-8.
21. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-42.
22. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2-12.
23. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655-64.
24. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12:6213s-6s.
25. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003; 88:5059-75.
26. Guise TA. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact 2002; 2:570-2.
27. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13:581-9.
28. Frith JC, Monkkonen J, Blackburn GM, et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997; 12:1358-67.
29. Lehenkari PP, Kellinsalmi M, Napankangas JP, et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002; 61:1255-62.
30. Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 2006; 39:443-52.
31. Body JJ, Dumon JC, Gineyts E, et al. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997; 75:408-12.
32. Lipton A. Bisphosphonates and breast carcinoma. Cancer 1997; 80:1668-73.
33. Berenson JR, Lipton A. Use of bisphosphonates in patients with metastatic bone disease. Oncology (Williston Park) 1998; 12:1573-9.
34. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002; 25:S10-8.
35. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91:1191-200.
36. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus Pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377-87.
37. Body JJ, Lichinitser M, Tjulandin S, et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 2007; 18:1165-71.
38. Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111:306-12.
39. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11:59-65.
40. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992; 340:1049-52.
41. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-63.
42. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90:704-8.
43. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19:10-7.
44. Saarto T, Vehmanen L, Virkkunen P, et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004; 43:650-6.
45. Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized doubleblind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007; 99:765-76.
46. Kohno N, Kokufu I. Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy. Breast Cancer 2003; 10:33-7.
47. Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22:195-201.
48. Paterson AH. The role of bisphosphonates in early breast cancer. Oncologist 2006; 11 (suppl 1):13-9.
49. Cvitkovic F, Armand JP, Tubiana-Hulin M, et al. Randomized, double-blind, phase II trial of gallium nitrate compared with Pamidronate for acute control of cancer-related hypercalcemia. Cancer J 2006; 12:47-53.
50. Warrell RP Jr, Bockman RS. Gallium in the treatment of hypercalcemia and bone metastasis. In: Devita VT, Rosenberg SA, Hellman S, eds.Important Advances in Oncology. Philadelphia, PA: J.B. Lippincott; 1989;205-20.
51. Warrell RP Jr, Murphy WK, Schulman P, et al. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991; 9:1467-75.
52. Laitala T, Vaananen HK. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase. J Clin Invest 1994; 93:2311-8.
53. Frattini A, Orchard PJ, Sobacchi C, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 2000; 25:343-6.
54. Leyland-Jones B, Bhalla RB, Farag F et al. Administration of gallium nitrate by continuous infusion: lack of chronic nephrotoxicity confirmed by studies of enzymuria and beta 2-microglobulinuria. Cancer Treat Rep 1983; 67:941-2.
55. Chitambar CR, Purpi DP, Woodliff J, et al. Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J Pharmacol Exp Ther 2007; 322:1228-36.
56. Chua MS, Bernstein LR, Li R, et al. Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res 2006; 26:1739-43.
57. Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A 1988; 85:7972-6.
58. Farina C, Gagliardi S, Nadler G, et al. Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase. Farmaco 2001; 56:113-6.
59. Visentin L, Dodds RA, Valente M, et al. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 2000; 106:309-18.
60. Niikura K. Vacuolar ATPase as a drug discovery target. Drug News Perspect 2006; 19:139-44.
61. Chitambar CR, Narasimhan J, Guy J, et al. Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 1991; 51:6199-201.
62. Warrell RP Jr, Danieu L, Coonley CJ, et al. Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate, and etoposide. Cancer Treat Rep 1987; 71:47-51.
63. Clausen J, Edeling CJ, Fogh J. 67Ga binding to human serum proteins and tumor components. Cancer Res 1974; 34:1931-7.
64. Bockman RS, Repo MA, Warrell RP Jr, et al. Distribution of trace levels of therapeutic gallium in bone as mapped by synchrotron x-ray microscopy. Proc Natl Acad Sci U S A 1990; 87:4149-53.
65. Vallabhajosula SR, Harwig JF, Siemsen JK, et al. Radiogallium localization in tumors: blood binding and transport and the role of transferrin. J Nucl Med 1980; 21:650-6.
66. Pavlakis N, Schmidt R, Stockier M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; (3):CD003474.
67. Kunin M, Kopolovic J, Avigdor A, et al. Collapsing glomerulopathy induced by long-term treatment with standard-dose Pamidronate in a myeloma patient. Nephrol Dial Transplant 2004; 19:723-26.
68. Body JJ, Diel IJ, Tripathy D, et al. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care 2006; 15:299-302.
69. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-91.
70. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99-102.
71. Chukwujindu J, Dolin P. Bisphosphonates and jaw osteonecrosis: updated experience with ibandronate. Presented at: the 31st European Society for Medical Oncoogy Congress; Istanbul, Turkey; September 29-October 3, 2006. Abstract 1001A.
72. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055-61.
73. Bezzi M, Hasmim M, Bieler G, et al. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003; 278:43603-14.
74. Dempster DW. The impact of bone turnover and bone-active agents on bone quality: focus on the hip. Osteoporos Int 2002; 13:349-52.
75. Reid IR. Zoledronate: efficacy and safety. J Bone Miner Res 2006; 21 (suppl 2):83-7.
76. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346:653-61.
77. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001; 98:11581-6.
78. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006; 25:541-9.
79. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97:887-92.
80. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-7.
81. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12:1221-8.
82. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25:4431-7.
83. Gralow J, Lipton A, Fizazi K, et al. Denosumab treatment of cancer patients with bone metastases and elevated urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a phase II randomized trial. Presented at: 2007 Breast Cancer Symposium; September 7-8, 2007; San Francisco, CA. Abstract 199.
84. Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103:41-50.
85. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440:692-6.
86. Kim N, Odgren PR, Kim DK, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A 2000; 97:10905-10.
87. Josien R, Li HL, Ingulli E, et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000; 191:495-502.
88. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in post-menopausal women with low bone mineral density. N Engl J Med 2006; 354:821-31.
89. Soriano P, Montgomery C, Geske R, et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64:693-702.
90. Sanjay A, Houghton A, Neff L, et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 2001; 152:181-95.
91. Wong BR, Besser D, Kim N, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999; 4:1041-9.
92. Schwartzberg PL, Xing L, Hoffmann O, et al. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/-mutant mice. Genes Dev 1997; 11:2835-44.
93. Boyce BF, Xing L, Yao Z, et al. SRC inhibitors in metastatic bone disease. Clin Cancer Res 2006; 12:6291s-5s.
94. Recchia I, Rucci N, Festuccia C, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003; 39:1927-35.
95. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006; 318:161-72.
96. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, et al. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 1992; 52:4773-8.
97. Verbeek BS, Vroom TM, Adriaansen-Slot SS, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996; 180:383-8.
98. Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 2007; 26:3503-10.
99. Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 2004; 82:263-74.
100. Myoui A, Nishimura R, Williams PJ, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003; 63:5028-33.
101. Boyce BF, Xing L, Shakespeare W, et al. Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int Suppl 2003; 85:S2-5.
102. Vu CB, Luke GP, Kawahata N, et al. Bone-targeted pyrido[2,3-d]pyrimidin- 7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents. Bioorg Med Chem Lett 2003; 13:3071-4.
103. Shakespeare WC, Metcalf CA III, Wang Y, et al. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr Opin Drug Discov Devel 2003; 6:729-41.
104. Eastell R, Hannon RA, Gallagher N, et al. The effect of AZD0530, a highly selective Src inhibitor, on bone turnover in healthy males. J Clin Oncol 2005; 23(16 suppl):202s (Abstract 3041).
105. Hannon RA, Clack G, Gallagher N. The effect of AZD0530, a highly selective Src inhibitor, on bone turnover in healthy males. Bone 2005; 36:S135.
106. Tabernero JA, Cervantes A, Hoekman K, et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: first demonstration of inhibition of Src activity in human cancers. J Clin Oncol 2007; 25:3520.
107. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84.
108. Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10:1165-77.
109. Miyashita T, Kawakami A, Nakashima T, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 2004; 137:430-6.
110. Kneissel M, Luong-Nguyen NH, Baptist M, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 2004; 35:1144-56.
111. Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 2004; 4:621-35.
112. Metcalf C, Bohacek R, Bogus J, et al. A novel, bone-targeted mTOR inhibitor that decreases both tumor proliferation and bone breakdown for the treatment of bone cancer. Presented at: 96th Annual Meeting of the American Association of Cancer Research; April 16-20, 2005; Anaheim, CA. Abstract 717.
113. Meunier PJ. [Strontium ranelate: new therapeutic agent for post-menopausal osteoporosis]. Med Sci (Paris) 2004; 20:631-3.
114. Farlay D, Boivin G, Panczer G, et al. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res 2005; 20:1569-78.
115. Sly WS, Hewett-Emmett D, Whyte MP, et al. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A 1983; 80:2752-6.
116. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350:459-68.
117. Delmas PD. Clinical effects of strontium ranelate in women with post-menopausal osteoporosis. Osteoporos Int 2005; 16(suppl 1):S16-9.
118. Troen BR. The regulation of cathepsin K gene expression. Ann N Y Acad Sci 2006; 1068:165-72.
119. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 1998; 95:13453-8.
120. Gelb BD, Shi GP, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273:1236-8.
121. Kato H, Matsuoka K, Kato N, et al. Mandibular osteomyelitis and fracture successfully treated with vascularised iliac bone graft in a patient with pycnodysostosis. Br J Plast Surg 2005; 58:263-6.
122. Jerome C, Missbach M, Gamse R. AAE581, a Novel cathepsin K inhibitor, protects against ovariectomy-induced bone loss in non-human primates, in part by stimulation of periosteal bone formation. Presented at: 27th Annual Meeting of the American Society of Bone and Mineral Research; September 23-27, 2005; Nashville, TN. Presentation 1179.
123. Itabashi A, Kurata N, Sugita Y, et al. Pharmacokinetics and pharmacodynamic effect of AAE581, a novel cathepsin K inhibitor in Japanese postmenopausal women. Osteoporos Int 2006; 17(supple 2):S216-7.
124. Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007; 40:122-31.
125. Sato Y, Sakai H, Kobayashi Y, et al. Bisphosphonate administration alters subcellular localization of vacuolar-type H(+)-ATPase and cathepsin K in osteoclasts during experimental movement of rat molars. Anat Rec 2000; 260:72-80.
126. Brubaker KD, Vessella RL, True LD, et al. mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003; 18:222-30.
127. Teitelbaum SL. Osteoclasts and integrins. Ann N Y Acad Sci 2006; 1068:95-9.
128. McHugh KP, Hodivala-Dilke K, Zheng MH, et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000; 105:433-40.
129. Murphy MG, Cerchio K, Stoch SA, et al. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005; 90:2022-8.
130. Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003; 4:123-31.
131. Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A 2003; 100:14205-10.
132. Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003; S32-8.
133. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26:688-703.
134. Kostenuik PJ, Capparelli C, Morony S, et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 2001; 142:4295-304.
135. Valenta A, Roschger P, Fratzl-Zelman N, et al. Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone 2005; 37:87-95.
136. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323:1-6.
137. Holloway L, Butterfield G, Hintz RL, et al. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994; 79:470-9.
138. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483-94.
139. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106:3160-5.
140. Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109:2106-11.
141. Zou W, Kitaura H, Reeve J, et al. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 2007; 176:877-88.
142. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006; 4:111-21.
143. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004; 64:2016-23.